| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
We performed yearly MRI analyses on 327 of the total 372 patients in a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-1b (IFNB). Clinical results are presented in the preceding companion paper. Baseline MRI characteristics were the same in all treatment groups. Fifty-two patients at one center formed a cohort for frequent MRIs (one every 6 weeks) for analysis of disease activity. The MRI results support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans (median 80% reduction, p = 0.0082) and appearance of new lesions. In addition, there was an equally significant reduction in MRI-detected burden of disease in the treatment as compared with placebo groups (mean group difference of 23%, p = 0.001). These results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients.
Address correspondence and reprint requests to Dr. Donald W. Paty, Division of Neurology, The University of British Columbia, 222-2775 Heather Street, Vancouver, BC, Canada V5Z 3J5.
Received February 6, 1993. Accepted for publication in final form February 12, 1993.
*See page 0000 for UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group participants.
This article has been cited by other articles:
|
|
 |
|
  P. K Coyle and D. R Jeffery Clinical efficacy and benefit of natalizumab Multiple Sclerosis, November 1, 2009; 15(4_suppl): S7 - S15. [Abstract] [PDF]
|
|
|
|
 |
|
 O. Stuve and R. M. Ransohoff Immunotherapy for Multiple Sclerosis: The Curious Case of Interferon Beta Arch Neurol, October 1, 2009; 66(10): 1193 - 1194. [Full Text] [PDF]
|
|
|
|
|
|
D. Goodin and D. Bates Review: Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode Multiple Sclerosis, October 1, 2009; 15(10): 1175 - 1182. [Abstract] [PDF]
|
|
|
|
|
|
X. Montalban, J. Sastre-Garriga, M. Tintore, L. Brieva, F. Aymerich, J. Rio, J. Porcel, C. Borras, C. Nos, and A. Rovira A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis Multiple Sclerosis, October 1, 2009; 15(10): 1195 - 1205. [Abstract] [PDF]
|
|
|
|
|
|
W. Carroll Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit Multiple Sclerosis, August 1, 2009; 15(8): 951 - 958. [Abstract] [PDF]
|
|
|
|
|
|
J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga, C Nos, M Comabella, X Aymerich, and X Montalban Measures in the first year of therapy predict the response to interferon {beta} in MS Multiple Sclerosis, July 1, 2009; 15(7): 848 - 853. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Koch-Henriksen No shortcuts to outcome in MS clinical trials? Neurology, February 24, 2009; 72(8): 686 - 687. [Full Text] [PDF]
|
|
|
|
|
|
A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 M. B. Forrester, L. Coleman, and A. J. Kornberg Multiple Sclerosis in Childhood: Clinical and Radiological Features J Child Neurol, January 1, 2009; 24(1): 56 - 62. [Abstract] [PDF]
|
|
|
|
 |
|
 The CAMMS223 Trial Investigators Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis N. Engl. J. Med., October 23, 2008; 359(17): 1786 - 1801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Deen, P Bacchetti, A High, and E Waubant Predictors of the location of multiple sclerosis relapse J. Neurol. Neurosurg. Psychiatry, October 1, 2008; 79(10): 1190 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Goodin, B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, September 2, 2008; 71(10): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Minneboo, B Jasperse, F Barkhof, B M J Uitdehaag, D L Knol, V de Groot, C H Polman, and J A Castelijns Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters J. Neurol. Neurosurg. Psychiatry, August 1, 2008; 79(8): 917 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Kraus, K Voigt, A. Schuller, M Scholz, K. Kim, M Schilling, W. Schabitz, P Oschmann, and B Engelhardt Interferon-{beta} stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro Multiple Sclerosis, July 1, 2008; 14(6): 843 - 852. [Abstract] [PDF]
|
|
|
|
|
|
L Durelli, P Barbero, M Bergui, E Versino, M A Bassano, E Verdun, C Rivoiro, C Ferrero, E Picco, P Ripellino, et al. MRI activity and neutralising antibody as predictors of response to interferon {beta} treatment in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Rio, A Rovira, M Tintore, E Huerga, C Nos, N Tellez, C Tur, M Comabella, and X Montalban Relationship between MRI lesion activity and response to IFN-{beta} in relapsing-remitting multiple sclerosis patients Multiple Sclerosis, May 1, 2008; 14(4): 479 - 484. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Duan, P.G. Hildenbrand, M.P. Sampat, D.F. Tate, I. Csapo, B. Moraal, R. Bakshi, F. Barkhof, D.S. Meier, and C.R.G. Guttmann Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2008; 29(2): 340 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang and J. C. Hsu Hochberg's Step-Up Method: Cutting Corners Off Holm's Step-Down Method Biometrika, December 1, 2007; 94(4): 965 - 975. [Abstract] [PDF]
|
|
|
|
|
|
K. Baum, C. O'Leary, F. Coret Ferrer, E. Klimova, L. Prochazkova, J. Bugge, and for the BRIGHT Study Group Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b Multiple Sclerosis, November 1, 2007; 13(9): 1153 - 1160. [Abstract] [PDF]
|
|
|
|
|
|
F. Barkhof, C. H. Polman, E.-W. Radue, L. Kappos, M. S. Freedman, G. Edan, H.-P. Hartung, D. H. Miller, X. Montalban, P. Poppe, et al. Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study: Integrated 2-Year Results Arch Neurol, September 1, 2007; 64(9): 1292 - 1298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Coyle Evidence-based medicine and clinical trials Neurology, June 12, 2007; 68(24_suppl_4): S3 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
O. Khan Can clinical outcomes be used to detect neuroprotection in multiple sclerosis? Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Arnold Evidence for neuroprotection and remyelination using imaging techniques Neurology, May 29, 2007; 68(22_suppl_3): S83 - S90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zivadinov, L. Locatelli, D. Cookfair, B. Srinivasaraghavan, A. Bertolotto, M. Ukmar, A. Bratina, C. Maggiore, A. Bosco, A. Grop, et al. I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy Multiple Sclerosis, May 1, 2007; 13(4): 490 - 501. [Abstract] [PDF]
|
|
|
|
|
|
L. Feuillet, J. Pelletier, L. Suchet, A. Rico, A. Ali Cherif, J. Pouget, and S. Attarian Prospective clinical and electrophysiological follow-up on a multiple sclerosis population treated with interferon beta-1 a: a pilot study Multiple Sclerosis, April 1, 2007; 13(3): 348 - 356. [Abstract] [PDF]
|
|
|
|
|
|
L. Kappos, C. H. Polman, M. S. Freedman, G. Edan, H. P. Hartung, D. H. Miller, X. Montalban, F. Barkhof, L. Bauer, P. Jakobs, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology, October 10, 2006; 67(7): 1242 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Maier, A. V. Kuhnert, N. Taheri, M. B. Sattler, M. K. Storch, S. K. Williams, M. Bahr, and R. Diem Effects of Glatiramer Acetate and Interferon-{beta} on Neurodegeneration in a Model of Multiple Sclerosis: A Comparative Study Am. J. Pathol., October 1, 2006; 169(4): 1353 - 1364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger The value of animal models for drug development in multiple sclerosis Brain, August 1, 2006; 129(8): 1940 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Gottesman and S Friedman-Urevich Interferon beta-1b (Betaseron(R)/Betaferon(R)) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS) Multiple Sclerosis, June 1, 2006; 12(3): 271 - 280. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Krapf, S. P. Morrissey, O. Zenker, T. Zwingers, R. Gonsette, H. -P. Hartung, and the MIMS Study Group Effect of mitoxantrone on MRI in progressive MS: Results of the MIMS trial Neurology, September 13, 2005; 65(5): 690 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M P Sormani, P Bruzzi, G Comi, and M Filippi The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis Multiple Sclerosis, August 1, 2005; 11(4): 447 - 449. [Abstract] [PDF]
|
|
|
|
|
|
C. H. Polman, L. Kappos, F. Dahlke, R. Graf, K. Beckmann, T. Bogumil, C. Pozzilli, A. J. Thompson, and the European Study Group on Interferon Beta-1b in Interferon beta-1b treatment does not induce autoantibodies Neurology, March 22, 2005; 64(6): 996 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11. [Abstract] [Full Text]
|
|
|
|
|
|
W. H. Stuart, S. Cohan, J. R. Richert, and A. Achiron Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S19 - S27. [Abstract] [Full Text]
|
|
|
|
|
|
L. Kappos, B. Weinshenker, C. Pozzilli, A. J. Thompson, F. Dahlke, K. Beckmann, C. Polman, H. McFarland, and for the European and North American Interferon b Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials Neurology, November 23, 2004; 63(10): 1779 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The North American Study Group on Interferon beta- Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study Neurology, November 23, 2004; 63(10): 1788 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. C. Zang, S. M Skinner, R. R Robinson, S. Li, V. M Rivera, G. J Hutton, and J. Z Zhang Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis Multiple Sclerosis, October 1, 2004; 10(5): 499 - 506. [Abstract] [PDF]
|
|
|
|
 |
|
 B. Bielekova, N. Richert, T. Howard, G. Blevins, S. Markovic-Plese, J. McCartin, J. Wurfel, J. Ohayon, T. A. Waldmann, H. F. McFarland, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon {beta} PNAS, June 8, 2004; 101(23): 8705 - 8708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Liuzzi, T. Latronico, A. Fasano, G. Carlone, and P. Riccio Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment Multiple Sclerosis, June 1, 2004; 10(3): 290 - 297. [Abstract] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(1_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
O. Stuve, M. Kita, D. Pelletier, R. J Fox, J. Stone, D. E Goodkin, and S. S Zamvil Mitoxantrone as a potential therapy for primary progressive multiple sclerosis Multiple Sclerosis, May 1, 2004; 10(3_suppl): S58 - S61. [Abstract] [PDF]
|
|
|
|
|
|
A J. Petkau, R. A White, G. C Ebers, A. T Reder, W. A Sibley, F. D Lublin, D. W Paty, and IFNB Multiple Sclerosis Study Group Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2004; 10(2): 126 - 138. [Abstract] [PDF]
|
|
|
|
|
|
K. Schmierer, D. R Altmann, N. Kassim, H. Kitzler, C. M Kerskens, C. A Doege, O. Aktas, J. D Lunemann, D. H Miller, F. Zipp, et al. Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study Multiple Sclerosis, April 1, 2004; 10(2): 182 - 187. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Frank, N. Richert, C. Bash, L. Stone, P. A. Calabresi, B. Lewis, R. Stone, T. Howard, and H. F. McFarland Interferon-{beta}-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients Neurology, March 9, 2004; 62(5): 719 - 725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Rashid, A Hadjiprocopis, C M Griffin, D T Chard, G R Davies, G J Barker, P S Tofts, A J Thompson, and D H Miller Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction Multiple Sclerosis, February 1, 2004; 10(1): 9 - 15. [Abstract] [PDF]
|
|
|
|
|
|
A. J. Petkau Statistical approaches to assessing the effects of neutralizing antibodies: IFN{beta}-1b in the pivotal trial of relapsing-remitting multiple sclerosis Neurology, November 11, 2003; 61(90095): S35 - 37. [Abstract] [Full Text]
|
|
|
|
|
|
L M. Grimaldi, A Pincherle, F Martinelli-Boneschi, M Filippi, F Patti, A Reggio, D Franciotta, L Allegra, G Comi, and F Blasi An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients Multiple Sclerosis, October 1, 2003; 9(5): 467 - 471. [Abstract] [PDF]
|
|
|
|
|
|
C Polman, F Barkhof, L Kappos, C Pozzilli, R Sandbrink, F Dahlke, P Jakobs, A Lorenz, and European Oral Interferon Beta-1a in Relapsing-Remi Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study Multiple Sclerosis, August 1, 2003; 9(4): 342 - 348. [Abstract] [PDF]
|
|
|
|
|
|
M. Inglese, J.H.T.M. van Waesberghe, M. Rovaris, K. Beckmann, F. Barkhof, D. Hahn, L. Kappos, D.H. Miller, C. Polman, C. Pozzilli, et al. The effect of interferon {beta}-1b on quantities derived from MT MRI in secondary progressive MS Neurology, March 11, 2003; 60(5): 853 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta Multiple Sclerosis, February 1, 2003; 9(1): 32 - 35. [Abstract] [PDF]
|
|
|
|
|
|
M. Rovaris, G. Comi, D. Ladkani, J. S. Wolinsky, and M. Filippi Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., January 1, 2003; 24(1): 75 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan Issues and Practices in Multiple Sclerosis Neurorehabil Neural Repair, December 1, 2002; 16(4): 307 - 320. [Abstract] [PDF]
|
|
|
|
 |
|
 S. L. Galetta, C. Markowitz, and A. G. Lee Immunomodulatory Agents for the Treatment of Relapsing Multiple Sclerosis: A Systematic Review Arch Intern Med, October 28, 2002; 162(19): 2161 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dasgupta, M. Jana, X. Liu, and K. Pahan Myelin Basic Protein-primed T Cells Induce Nitric Oxide Synthase in Microglial Cells. IMPLICATIONS FOR MULTIPLE SCLEROSIS J. Biol. Chem., October 11, 2002; 277(42): 39327 - 39333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O'Connor Key issues in the diagnosis and treatment of multiple sclerosis: An overview Neurology, September 24, 2002; 59(90063): S1 - 33. [Full Text]
|
|
|
|
|
|
A. B. Rao, N. Richert, T. Howard, B.K. Lewis, C.N. Bash, H.F. McFarland, and J. A. Frank Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFN{beta}-1b Neurology, September 10, 2002; 59(5): 688 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Coyle and H-P. Hartung Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response Multiple Sclerosis, September 1, 2002; 8(1_suppl): 2 - 9. [Abstract] [PDF]
|
|
|
|
|
|
M. Freedman, L. Blumhardt, B. Brochet, G. Comi, J. Noseworthy, M. Sandberg-Wollheim, and P. Soelberg Sorensen International consensus statement on the use of disease-modifying agents in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
J. Frank, N. Richert, B. Lewis, C. Bash, T. Howard, R. Civil, R. Stone, J. Eaton, H. McFarland, and T. Leist A pilot study of recombinant insulin-like growth factor-I in seven multiple sclerosis patients Multiple Sclerosis, September 1, 2002; 8(1_suppl): 24 - 29. [Abstract] [PDF]
|
|
|
|
|
|
H. McFarland, F. Barkhof, J. Antel, and D. Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, September 1, 2002; 8(1_suppl): 40 - 51. [Abstract] [PDF]
|
|
|
|
|
|
C M Dalton, P A Brex, R Jenkins, N C Fox, K A Miszkiel, W R Crum, J I O'Riordan, G T Plant, A J Thompson, and D H Miller Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2002; 73(2): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Chappell and H. Cohen Frontiers in Neuropharmacotherapy Part II: Multiple Sclerosis and Parkinson's Disease Journal of Pharmacy Practice, June 1, 2002; 15(3): 221 - 240. [Abstract] [PDF]
|
|
|
|
|
|
I. Shoulson Experimental Neurotherapeutics: Leaps and Bounds Arch Neurol, May 1, 2002; 59(5): 689 - 691. [Full Text] [PDF]
|
|
|
|
|
|
K. Bashir and J. N. Whitaker Current Immunotherapy for Demyelinating Diseases Arch Neurol, May 1, 2002; 59(5): 726 - 731. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Calabresi Considerations in the treatment of relapsing-remitting multiple sclerosis Neurology, April 23, 2002; 58(90084): S10 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
C Gasperini, A Paolillo, E Giugni, S Galgani, F Bagnato, C Mainero, E Onesti, S Bastianello, and C Pozzilli MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a Multiple Sclerosis, April 1, 2002; 8(2): 119 - 123. [Abstract] [PDF]
|
|
|
|
|
|
P K Coyle and H-P Hartung Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response Multiple Sclerosis, February 1, 2002; 8(1): 2 - 9. [Abstract] [PDF]
|
|
|
|
|
|
M S Freedman, L D Blumhardt, B Brochet, G Comi, J H Noseworthy, M Sandberg-Wollheim, P S. Sorensen, and Paris Workshop Group International consensus statement on the use of disease-modifying agents in multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 19 - 23. [Abstract] [PDF]
|
|
|
|
|
|
J A Frank, N Richert, B Lewis, C Bash, T Howard, R Civil, R Stone, J Eaton, H McFarland, and T Leist A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients Multiple Sclerosis, February 1, 2002; 8(1): 24 - 29. [Abstract] [PDF]
|
|
|
|
|
|
H F McFarland, F Barkhof, J Antel, and D H Miller The role of MRI as a surrogate outcome measure in multiple sclerosis Multiple Sclerosis, February 1, 2002; 8(1): 40 - 51. [Abstract] [PDF]
|
|
|
|
 |
|
 R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, G. P. Garmany Jr., J. Halper, W. H. Likosky, F. D. Lublin, D. H. Silberberg, W. H. Stuart, and S. van den Noort Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology, January 22, 2002; 58(2): 169 - 178. [Full Text] [PDF]
|
|
|
|
|
|
E. Bech, J. Lycke, P. Gadeberg, H.J. Hansen, C. Malmestrom, O. Andersen, T. Christensen, S. Ekholm, S. Haahr, P. Hollsberg, et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS Neurology, January 8, 2002; 58(1): 31 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Faro, F. B. Mohamed, J. I. Tracy, R. M. Elfont, A. B. Pinus, F. D. Lublin, R. A. Koenigsberg, C. Y. Chen, and F. Y. Tsai Quantitative Functional MR Imaging of the Visual Cortex at 1.5 T as a Function of Luminance Contrast in Healthy Volunteers and Patients with Multiple Sclerosis AJNR Am. J. Neuroradiol., January 1, 2002; 23(1): 59 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Molyneux, G. J. Barker, F. Barkhof, K. Beckmann, F. Dahlke, M. Filippi, M. Ghazi, D. Hahn, D. MacManus, C. Polman, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS Neurology, December 26, 2001; 57(12): 2191 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M Griffin, D. T Chard, O. Ciccarelli, R. Kapoor, G. J Barker, A. J Thompson, and D. H Miller Diffusion tensor imaging in early relapsing-remitting multiple sclerosis Multiple Sclerosis, October 1, 2001; 7(5): 290 - 297. [Abstract] [PDF]
|
|
|
|
|
|
E. M. Frohman, H. Zhang, P. D. Kramer, J. Fleckenstein, K. Hawker, M. K. Racke, and T. C. Frohman MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis Neurology, September 11, 2001; 57(5): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Barkhof, J.-H. T. M. van Waesberghe, M. Filippi, T. Yousry, D. H. Miller, D. Hahn, A. J. Thompson, L. Kappos, P. Brex, C. Pozzilli, et al. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment Brain, July 1, 2001; 124(7): 1396 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
European Study Group on Interferon-Beta-1a in MS Double-blind randomized multicenter dose-comparison study of interferon-{beta}-1a (AVONEX): rationale, design and baseline data Multiple Sclerosis, June 1, 2001; 7(3): 179 - 183. [Abstract] [PDF]
|
|
|
|
|
|
N D Richert, J L Ostuni, C N Bash, T P Leist, H F McFarland, and J A Frank Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis Multiple Sclerosis, February 1, 2001; 7(1): 49 - 58. [Abstract] [PDF]
|
|
|
|
|
|
J. A. Koziol, S. Wagner, D. F. Sobel, L. S. Slivka, J. S. Romine, J. C. Sipe, and H.-P. Adams Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis AJNR Am. J. Neuroradiol., February 1, 2001; 22(2): 284 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Rudick, E. Fisher, J.-C. Lee, J. T Duda, and J. Simon Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon {beta}-1a Multiple Sclerosis, December 1, 2000; 6(6): 365 - 372. [Abstract] [PDF]
|
|
|
|
|
|
G. Ebers MRI: measure of efficacy Brain, November 1, 2000; 123(11): 2187 - 2188. [Full Text] [PDF]
|
|
|
|
|
|
P. D. Molyneux, L. Kappos, C. Polman, C. Pozzilli, F. Barkhof, M. Filippi, T. Yousry, D. Hahn, K. Wagner, M. Ghazi, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis Brain, November 1, 2000; 123(11): 2256 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Janardhan and R. Bakshi Quality of Life and Its Relationship to Brain Lesions and Atrophy on Magnetic Resonance Images in 60 Patients With Multiple Sclerosis Arch Neurol, October 1, 2000; 57(10): 1485 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Noseworthy, C. Lucchinetti, M. Rodriguez, and B. G. Weinshenker Multiple Sclerosis N. Engl. J. Med., September 28, 2000; 343(13): 938 - 952. [Full Text] [PDF]
|
|
|
|
|
|
T. F. Scott, C. J. Schramke, J. Novero, and C. Chieffe Short-term prognosis in early relapsing-remitting multiple sclerosis Neurology, September 12, 2000; 55(5): 689 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C H Polman and B M J Uitdehaag Regular review: Drug treatment of multiple sclerosis BMJ, August 19, 2000; 321(7259): 490 - 494. [Full Text]
|
|
|
|
|
|
P. D Molyneux, P. A Brex, C. Fogg, S. Lewis, C. Middleditch, F. Barkhof, M. P Sormani, M. Filippi, and D. H Miller The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study Multiple Sclerosis, August 1, 2000; 6(4): 237 - 240. [Abstract] [PDF]
|
|
|
|
|
|
B. L. McRae, T. Nagai, R. T. Semnani, J. M. van Seventer, and G. A. van Seventer Interferon-alpha and -beta inhibit the in vitro differentiation of immunocompetent human dendritic cells from CD14+ precursors Blood, July 1, 2000; 96(1): 210 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V L Stevenson, D H Miller, S M Leary, M Rovaris, F Barkhof, B Brochet, V Dousset, V Dousset, M Filippi, R Hintzen, et al. One year follow up study of primary and transitional progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 713 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Koch-Henriksen, P. S. Surensen, and The Danish Multiple Sclerosis Group The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2000; 6(3): 172 - 175. [Abstract] [PDF]
|
|
|
|
 |
|
 G. B. Pike, N. De Stefano, S. Narayanan, K. J. Worsley, D. Pelletier, G. S. Francis, J. P. Antel, and D. L. Arnold Multiple Sclerosis: Magnetization Transfer MR Imaging of White Matter before Lesion Appearance on T2-weighted Images Radiology, June 1, 2000; 215(3): 824 - 830. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Scanderbeg, F. Tomaiuolo, U. Sabatini, U. Nocentini, M. G. Grasso, and C. Caltagirone Demyelinating Plaques in Relapsing-remitting and Secondary-progressive Multiple Sclerosis: Assessment with Diffusion MR Imaging AJNR Am. J. Neuroradiol., May 1, 2000; 21(5): 862 - 868. [Abstract] [Full Text]
|
|
|
|
|
|
A. O. Nusbaum, C. Y. Tang, T.-C. Wei, M. S. Buchsbaum, and S. W. Atlas Whole-brain diffusion MR histograms differ between MS subtypes Neurology, April 11, 2000; 54(7): 1421 - 1427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Kremenchutzky, D Lee, G P A Rice, and G C Ebers Diagnostic brain MRI findings in primary progressive multiple sclerosis Multiple Sclerosis, April 1, 2000; 6(2): 81 - 85. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
